EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...

There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska ...

Tilray Brands announced on Monday a new scientific publication supported by Tilray Medical. The study examines the real-world impact of cannabinoid treatments on patients with fibromyalgia. The study ...

Feeling like we have a degree of control makes us tolerate pain better. In the case of fibromyalgia, however, this simply doesn't work. A study provides clues as to why. Feeling like we have a degree ...

Aptinyx Inc. (NASDAQ:APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. The Phase 2b clinical study was designed to evaluate the ...

Overactive bladder (OAB) is prevalent among women with fibromyalgia (FM) and is associated with higher symptom severity and comorbidity, according to a study published in Neurourology Urodynamics.

Long COVID Afflicts Approximately 19% of Patients Following COVID-19 1, and is Expected to be a Global Health Burden Fibromyalgia-Type Long COVID with Multi-Site Pain Affects Approximately 40% of Long ...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...

Enrollment Continues in Phase 3 RELIEF Study, with Interim Results of the First 50 Percent of Participants Expected in September 2020 Topline Results of Approximately 470 Participants with ...

LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the ...